The impact of the immunological context on outcomes of solid cancer patients treated with genotype-matched targeted therapies: a comprehensive review.

This review explores the immunobiological features which may underlie this differential response.

本综述探讨了可能导致这种差异性反应的免疫生物学特征。

Methods

We conducted a literature review of studies assessing the impact of immune context following searches on Web of Science, Medline and Embase.

我们在Web of Science、Medline和Embase上进行了文献回顾，评估了免疫背景影响的研究。

Relevant outcomes include response, progression-free survivaland overall survival. Data were extracted from multivariate analysis, univariate analysis or directly from Kaplan-Meier curves.

相关结果包括反应、无进展生存期和总生存期。数据是通过多变量分析、单变量分析或直接从Kaplan-Meier曲线中提取的。

Meta-analyses were carried out where three or more studies analysed the same immune factor for the same cancer type.

进行了荟萃分析，其中三个或更多的研究分析了同一免疫因子对于同一种癌症类型。

The remaining studies were analysed descriptively.

剩余的研究进行了描述性分析。

Results

In the adjuvant setting, assessment of the immune context does not highlight a group failing to derive benefit for the use of dabrafenib/trametinib after resection of BRAFV600E melanoma.

在辅助治疗环境中，对免疫环境的评估并未显示出一组患者在切除BRAFV600E黑色素瘤后使用达拉非尼/曲美替尼无法获得益处。

Differential gene expression in exceptional responders show enrichment of genes associated with immune activation.

在极佳反应者中，差异基因表达显示出与免疫激活相关的基因富集。

BRAFV600E colorectal cancer patients with high cytolytic scores benefit from the addition of MEK inhibition whereas those with low scores fare better without.

具有高细胞溶解评分的BRAFV600E结直肠癌患者从添加MEK抑制剂中受益，而低评分患者则不加MEK抑制剂的治疗效果更好。

High programmed death-ligand 1 (PD-L1) expression is predictive of inferior outcomes to epidermal growth factor receptor (EGFR), ALK and G12C tyrosine kinase inhibitors.

高程序性死亡配体1（PD-L1）表达预示着对表皮生长因子受体（EGFR）、ALK和G12C酪氨酸激酶抑制剂的不良预后。

EGFR-mutant patients with high CD8+ T cells and PD-L1 positivity have very poor outcomes.

EGFR突变患者中，高CD8+ T细胞和PD-L1阳性者预后非常差。

Stromal tumour-infiltrating lymphocytes predict for efficacy of stromal-poor tumours in human epidermal growth factor receptor 2 (HER2)-positive breast cancer treated with short-course adjuvant trastuzumab.

基质肿瘤浸润淋巴细胞可预测在人类表皮生长因子受体2（HER2）阳性乳腺癌中，接受短期辅助曲妥珠单抗治疗的基质贫乏肿瘤的疗效。

High immune metagene and single immune gene expression are predictive of benefit for chemotherapy plus trastuzumab, but not chemotherapy alone.

高免疫元基因和单个免疫基因表达可预测化疗联合曲妥珠单抗的益处，但对单纯化疗无效。

The addition of pertuzumab or lapatanib appears to be beneficial in those with immune non-enriched microenvironments.

在免疫非富集微环境中，加入帕妥珠单抗或拉帕替尼似乎有益。

High major histocompatibility complex (MHC)-I is negatively predictive and high MHC-II is positively predictive of outcomes with trastuzumab-based therapy.

高主要组织相容性复合体（MHC）-I对曲妥珠单抗为基础的治疗结果具有负向预测性，而高MHC-II则具有正向预测性。

Conclusions

To our knowledge, this is the first review assessing immunological context as a biomarker for targeted therapy.

据我们所知，这是第一篇评估免疫学背景作为靶向治疗生物标志物的综述。

The results of this review represent an important resource to aid future translational studies in advancing stratified precision medicine oncology.

本综述的结果代表了重要的资源，有助于未来转化研究推进分层精准医学肿瘤学的发展。